First Over-the-counter Birth Control Pill in the US Set To Be on Sale Later This Month

birth control pills Opill women Over the Counter

By Jackelyn Cornejo , Parent Herald Mar 05, 12:55 am

Opill, the pioneering over-the-counter birth control pill available without a prescription, is set to launch later this month both online and in pharmacies, priced at $19.99 per month, $49.99 for a three-month supply, or $89.99 for a six-month supply, according to its parent company, Perrigo.

First Over-the-Counter Birth Control Pill in the US

By eradicating the need for a prescription, Opill target to simplify access to birth control, possibly overcoming barriers similar to cost and geographical constraints.

The FDA authorized its over-the-counter use in July after 50 years as a prescription drug.

Opill is expected to be sold at leading retailers like CVS and Walgreens and can be ordered through its website, with preorders beginning this week However, the cost may strike accessibility, especially for those without insurance, as state laws respecting coverage for non-prescription birth control differ.

Opill plans to propose a cost-assistance program in the coming weeks to support low-income, uninsured individuals in obtaining the product at reduced or no cost.

The Food and Drug Administration granted approval for Opill last year, allowing the United States to join other countries that have already embraced over-the-counter birth control pills.

Opill, which utilizes the hormone progestin to prevent pregnancy, is designed for daily use at the same time and boasts 98% effectiveness when used as directed.

Positive Impact to Current Healthcare System

The announcement of Opill into the market corresponds with a challenging period for US reproductive rights, with the latest setbacks to the national right to abortion by the Supreme Court. Amidst these difficulties, the arrival of Opill has been welcomed as a positive development by reproductive rights advocates.

Dr. Tracey Wilkinson, a pediatrician and board member with Physicians for Reproductive Health, conveyed support at the prospect of enhanced birth control access.

Despite the celebration, concerns have been raised about the proposed retail price of Opill, set at $19.99 for a one-month supply and $49.99 for a three-month supply. Some activists argue that this pricing may be excessive for teenagers and individuals facing financial restraint.

While the news of Opill's availability is considered a significant advancement, the focus remains on assuring affordable and accessible contraception, especially for young people navigating the complexities of the latest healthcare system.

The U.S. Food and Drug Administration acknowledged approval for the over-the-counter use of Opill last summer, marking an important departure from the past requirement of a prescription for birth control pills.

Opill, containing only the hormone progestin, is intended for daily use at consistent times and offers up to 98% effectiveness in preventing pregnancy when taken as directed.

While Opill presents a convenient option for many, it is essential to be aware of potential side effects such as bleeding, bloating, and abdominal pain. Women experiencing severe and persistent side effects are advised to consult their doctor.

Opill is not recommended for women with a history of breast cancer or those using other forms of hormonal birth control, such as an IUD, patch, or implant.